White Papers
2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a product, we…
Read Now
White Papers
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success.
In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…
Read Now
White Papers
Cell and Gene Therapy (CGT) is an exciting new frontier in the biopharmaceutical industry. The novelty of the technology and market introduces many complexities for companies commercializing CGTs.
This white paper analyzes the challenges faced and outlines six key questions to consider for reducing complexity and supporting commercial success:
Are we confident in the supply chain right up until administration of the treatment to the patient? Do we have the right pricing, reimbursement, and evidence model in place, not just…
Read Now
White Papers
New targeted oncology treatment regimens have changed cancer treatment. This white paper charts that development and analyzes five different approaches, providing an overview of how these paradigms determine strategic choices for commercial success. We observe that:
The oncology treatment landscape has five distinct treatment paradigms.
Competition, routes of administration, and market dynamics differ dramatically for each paradigm.
The approach to commercialization needs to differ for each paradigm to increase uptake and ensure successful market penetration.
Download the White Paper…
Read Now
Scientific Publications
This retrospective analysis of medical chart data was performed to compare severity and treatment of gout in patients with or without a history of kidney transplantation (KT).
Authors
Lauren Radeck, Clive M. Mendonca, Isabel Lang, Jeffrey Kent, Brian Lamoreaux, Richard J. Johnson
Journal
American Society of Nephrology Meeting, October 2018
View publication…
Read Now
White Papers
Trinity has worked with over a third of companies with cell and gene therapies (CGTs) on market or in Phase 3 clinical trials. Our work has supported business development, launch planning, evidence generation (HEOR, etc.), market access, pricing, and other critical commercial activities to support the development and launch of these therapies. As such, we have seen CGTs morph from a small niche into possibly the most exciting market in pharma. 2019 is poised to be an inflection point for…
Read Now
White Papers
The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose…
Read Now
Briefs
By Curt Staab, TGaS® Advisors, a division of Trinity
Executive Summary
TGaS® Advisors’ Emerging Life Sciences Network (elsN) has gathered advice and lessons learned from a broad-based CCO peer network to create this guide, the first in a series designed to help CCOs manage day-to-day and for the long-term. In this White Paper, we provide an overview of a CCO’s responsibilities, resources and expectations. Future issues will offer advice from peers and experts on launch planning and hiring.
To learn more,…
Read Now
Scientific Publications
Age and frailty are risk factors for overactive bladder (OAB), but less is known about their association with OAB burden.
Authors
Amod Athavale, Marissa Suh, Ali Haber, Jillian Godfrey Scaife, Nandini Hadker, Katherine Gooch
Journal
AGS Annual Meeting, May 2019
View publication…
Read Now
Scientific Publications
Genitourinary syndrome of menopause (GSM) is a chronic, progressive condition affecting up to 60% of post-menopausal women in the United States. Dyspareunia, or pain with sexual intercourse, has been recognized as one of GSM’s most bothersome symptoms. Despite high prevalence and availability of treatments, many women are not adequately managed, and unmet need remains. The objective of this systematic literature review was to characterize the unmet need.
Authors
S.S. Faubion, S.S. Karkare, K.R. Hennegan, N. Hadker, B.R. Robinson, M.Z. Lim-Watson…
Read Now
